The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial

DiscussionDISCOVER-2 findings informed the design of APEX, a Phase 3b study intended to further evaluate the impact of guselkumab in patients with active PsA and known risk factors for radiographic progression.Trial registrationThis trial was registered at ClinicalTrials.gov,NCT04882098. Registered on 11 May 2021.

http://link.springer.com/10.1186/s13063-022-06945-y

Source: Trials - January 10, 2023 Category: Research Source Type: clinical trials